We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 07, 2022

PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Lancet Oncol 2022 Oct 14;[EPub Ahead of Print], JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, RJ Francis, AY Zhang, AM Scott, ST Lee, AA Azad, MM McJannett, MR Stockler, SG Williams, ID Davis, MS Hofman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading